Morsingatkins3938
d by waist circumference (WC), being hypertensive or diabetic, and having a lower adherence to the traditional pattern increases WC. Conclusion removing excess zeroes from FFQ data it was possible to obtain well-defined eating patterns using the exploratory and confirmatory analysis, and to associate them with obesity through SEMs.
Background feelings and behaviours are an important tool that should be considered to prevent early unhealthy lifestyles. Objective the objective was to determine the association between feelings (i.e., sadness, loneliness, and school behaviour) with lifestyle (i.e., physical activity patterns and nutritional level), and as secondary endpoint to determine the relationship between health-related quality of life (HRQoL) and lifestyle with obesity and cardiometabolic risk (CMR) factors in Latin American schoolchildren. Methods this cross-sectional study included a sample of 634 schoolchildren (girls, n = 282, 11.86 ± 0.82 years, and boys, n = 352, 12.02 ± 0.87 years) from publics schools in Chile. Body mass index (BMI), waist circumference (WC), waist-to-height ratio (WtHR), body fat (BF), lifestyle, nutritional level, HRQoL, and CMR (i.e., WtHR > 0.5) were evaluated. Results schoolchildren who have felt sadness and loneliness presented an association with low nutritional level (OR 4.26, 95 % CI 2.0-9.0, p 1, respectively), bad lifestyle (OR 2.14, 95 % CI 1.0-4.54, p = 0.048, and OR 1.78, 95 % CI 1.01-3.1, p = 0.045, respectively), and obesity (OR 2.0, 95 % CI; 0.89-4.54, p = 0.09, and OR 2.05, 95 % CI; 1.04-4.0, p = 0.037, respectively). Schoolchildren who have had enough time for themselves reported an association with bad lifestyle (OR 0.69, 95 % CI 0.47-1.02, p = 0.06), and those who have could not pay attention presented the highest association with bad lifestyle (OR 4.64, 95 % CI 72-12.56, p = 0.002). Conclusion Latin American schoolchildren who have felt sadness and loneliness reported unhealthy lifestyles (i.e., lower nutritional level, increased screen time, and low physical activity), obesity, and thus a higher CMR burden.Fertility is a function of the body that often is overlooked as a site for the expression of the side effects of certain drugs. With the approval of new drugs with a totally innovative mechanism of action, the risk assessment on fertility both in male and female is more difficult. This is particularly true in psoriasis, an invalidating inflammatory skin disease. The estimated prevalence of psoriasis in adults ranged from 0.51% to 11.43%, and in children from 0% to 1.37%, with frequent diagnosis in young patients of childbearing age. With the increasing use of new, predominantly immunosuppressive or biologic drugs for psoriasis, questions frequently arise in clinical practice as to their safety in men and women wishing to procreate. Both psoriatic patients and their physicians are concerned about adverse effects of the disease and its treatment on their future fertility, causing additional concerns in the therapeutic management of these patients. Among anti-psoriatic drugs, conventional therapies are mainly involved in the onset of infertility in both sexes, exerting in some cases toxic effects against reproductive organs. Conversely, biologic agents appear to improve male and female fertility especially when gonadal impairment is related to inflammatory phenomena. There is a lack of review articles of commonly used medications in psoriasis with respect to their potential effects on fertility. Amredobresib concentration This paper aims to provide a practical guide for both dermatologist and endocrinologist in therapeutic management of psoriatic patients of childbearing age, considering the impact of prescribed drugs on their current and future fertility.
Differential diagnosis between constitutional delay of growth and puberty (CDGP), partial growth hormone deficiency (pGHD) and congenital hypogonadotropic hypogonadism (cHH) may be difficult. All these conditions usually present with poor growth in pre- or peri-pubertal age and they may recur within one familial setting, constituting a highly variable, but somehow common, spectrum of pubertal delay.
Narrative review of the most relevant English papers published between 1981 and march 2020 using the following search terms "constitutional delay of growth and puberty," "central hypogonadism," "priming," "growth hormone deficiency," "pituitary," "pituitary magnetic resonance imaging," with a special regard to the latest scientific acquisitions.
CDGP is by far the most prevalent entity in boys and recurs within families. pGHD is a rare, often idiopathic and transient condition, where hypostaturism presents more severely. Specificity of pGHD diagnosis is increased by priming children before growth hormone stimulation test (GHST); pituitary MRI and genetic analysis are recommended to personalize future follow-up. Diagnosing cHH may be obvious when anosmia and eunuchoid proportions concomitate. However, cHH can either overlap with pGHD in forms of multiple pituitary hormone deficiencies (MPHD) or syndromic conditions either with CDGP in family pedigrees, so endocrine workup and genetic investigations are necessary. The use of growth charts, bone age, predictors of adult height, primed GHST and low dose sex steroids (LDSS) treatment are recommended.
Only a step-by-step diagnostic process based on appropriate endocrine and genetic markers together with LDSS treatment can help achieving the correct diagnosis and optimizing outcomes.
Only a step-by-step diagnostic process based on appropriate endocrine and genetic markers together with LDSS treatment can help achieving the correct diagnosis and optimizing outcomes.
An association between Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) and risk of pancreatitis and pancreatic cancer has been suggested. Since its first description, several new trials (including three cardiovascular outcome trials) have been published, substantially increasing the available data set. This suggests the need for an update of the previous meta analysis.
A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials, with duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placebo or any other non-GLP-1 receptor agonist drug. The endpoints were pancreatitis, pancreatic cancer reported as serious adverse events. Mantel-Haenszel odds ratio (MH-OR) with 95% Confidence Interval (95% CI) was calculated for all outcomes defined above, on an intention-to-treat basis.
A total of 43 trials fulfilling inclusion criteria (all reporting data on pancreatitis and pancreatic cancer) was identified.
